RCUS ▼ -7.0% - Arcus Biosciences, Inc. $RCUS down pm RCUS Arcus Biosciences: Shares Fall 12.3% Following Updated Casdatifan Kidney Cancer Data ? • Heavily pretreated patients achieved median overall survival of nearly three years. • Phase 3 development is ongoing, with additional trials and a registrational combination study planned. • No clear catalyst has been identified for the selloff. 20-OCT-2026 08:40 AM ET